The combination of the EGFR–MET bispecific antibody amivantamab with the third-generation EGFR TKI lazertinib also showed a synergistic inhibition of tumor growth and a good safety profile in a cohort of EGFR-mutant NSCLC patients with resistance to osimertinib in a phase 1 trial, CHRYSALIS [34]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.